Y-mAbs Therapeutics, Inc. — Net Income by Fiscal Year
8 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/1325a6a2-1812-4156-8a1b-d829c614d49a/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2024 | $-29.7M | 2024-01-01 – 2024-12-31 | evidence 0001558370-25-002105 |
| FY 2023 | $-21.4M | 2023-01-01 – 2023-12-31 | evidence 0001558370-24-002188 |
| FY 2022 | $-95.6M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-005073 |
| FY 2021 | $-55.3M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-002567 |
| FY 2020 | $-119.3M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-002172 |
| FY 2019 | $-81.0M | 2019-01-01 – 2019-12-31 | evidence 0001558370-20-002551 |
| FY 2018 | $-43.3M | 2018-01-01 – 2018-12-31 | evidence 0001558370-19-002375 |
| FY 2017 | $-19.2M | 2017-01-01 – 2017-12-31 | evidence 0001558370-19-002375 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Y-mAbs Therapeutics, Inc. — all facts · Revenue · Operating Income